全文获取类型
收费全文 | 212224篇 |
免费 | 18132篇 |
国内免费 | 6299篇 |
专业分类
耳鼻咽喉 | 1327篇 |
儿科学 | 3438篇 |
妇产科学 | 2065篇 |
基础医学 | 31500篇 |
口腔科学 | 5739篇 |
临床医学 | 15462篇 |
内科学 | 32471篇 |
皮肤病学 | 3123篇 |
神经病学 | 16663篇 |
特种医学 | 5769篇 |
外国民族医学 | 40篇 |
外科学 | 27221篇 |
综合类 | 25916篇 |
现状与发展 | 25篇 |
预防医学 | 11495篇 |
眼科学 | 2318篇 |
药学 | 29578篇 |
114篇 | |
中国医学 | 8884篇 |
肿瘤学 | 13507篇 |
出版年
2024年 | 583篇 |
2023年 | 3447篇 |
2022年 | 7437篇 |
2021年 | 8981篇 |
2020年 | 7879篇 |
2019年 | 8205篇 |
2018年 | 7914篇 |
2017年 | 7582篇 |
2016年 | 7474篇 |
2015年 | 8127篇 |
2014年 | 13210篇 |
2013年 | 14025篇 |
2012年 | 12389篇 |
2011年 | 14351篇 |
2010年 | 11648篇 |
2009年 | 11022篇 |
2008年 | 10532篇 |
2007年 | 9402篇 |
2006年 | 8129篇 |
2005年 | 7354篇 |
2004年 | 6252篇 |
2003年 | 5375篇 |
2002年 | 4207篇 |
2001年 | 3646篇 |
2000年 | 2911篇 |
1999年 | 2812篇 |
1998年 | 2420篇 |
1997年 | 2240篇 |
1996年 | 2005篇 |
1995年 | 1867篇 |
1994年 | 1688篇 |
1993年 | 1670篇 |
1992年 | 1368篇 |
1991年 | 1231篇 |
1990年 | 1060篇 |
1989年 | 894篇 |
1988年 | 846篇 |
1987年 | 751篇 |
1986年 | 847篇 |
1985年 | 1640篇 |
1984年 | 1822篇 |
1983年 | 1402篇 |
1982年 | 1562篇 |
1981年 | 1384篇 |
1980年 | 1097篇 |
1979年 | 969篇 |
1978年 | 670篇 |
1977年 | 536篇 |
1976年 | 595篇 |
1975年 | 429篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
目的探讨对先天性耳甲腔型小耳畸形患者行全扩张法全耳再造术后,利用残耳皮瓣改善再造耳颅耳沟的效果。方法回顾分析 2012 年 1 月—2017 年 1 月收治的 150 例先天性耳甲腔型小耳畸形患者。其中男 92 例,女 58 例;年龄 6.5~35.0 岁,平均 11.1 岁。采用一期扩张器埋置、二期全扩张法全耳再造术后发现上部颅耳沟浅显;于 6~12 个月后行三期再造耳修整。将残耳垂通过“Z”字改型转移以再造耳垂。在残耳上部作蒂在轮屏切迹的残耳上部皮瓣,弧形切开松解并加深上部颅耳沟,将上部残耳皮瓣向颅耳沟创面旋转推进缝合以覆盖创面;将带皮下组织蒂的残耳软骨组织瓣插入支架底部形成的腔隙内,并缝合固定,以增加支架的高度;耳甲腔区其余残耳皮瓣用以覆盖耳甲腔创面。结果术后拆线时 1 例患儿皮瓣远端出现直径约 0.5 cm 的表皮水疱,经换药 2 周后愈合;其余患者皮瓣成活良好。患者均获随访,随访时间 6~12 个月,平均 9.6 个月。再造耳上部颅耳沟均明显加深,再造耳支架高度不同程度增加,双耳对称性佳,耳甲腔无明显挛缩变小,再造耳外观满意。再造耳上部表面毛发明显减少,耳周发际线上移。结论采用耳甲腔型小耳畸形的残耳皮瓣及残耳软骨瓣转移,不仅可加深颅耳沟,而且可增加上部支架的高度,术后颅耳沟变形较轻,再造耳与正常耳廓的对称性更佳。 相似文献
63.
目的 收集藿香正气汤的主要活性成分,通过分子对接及网络药理学探讨其防控新型冠状病毒肺炎(COVID-19)的有效成分及治疗机制。方法 通过基于配体-蛋白质相互作用的计算方法,以瑞德西韦为对照,探索藿香正气汤潜在治疗COVID-19的成分,并选出对接较好成分进行药理学机制预测,初探其药理学机制。结果 本研究筛选出5种与新冠病毒3CLpro结合能力强于瑞德西韦的小分子成分。网络药理学初步预测抗病毒途径可能是通过PI3K-Akt 信号通路影响病毒复制。结论 成分C1-C5与3CLpro结合良好,推测其可能是潜在的3CLpro的抑制剂,为抗病毒天然药物的开发提供了理论依据。 相似文献
64.
目的:探讨老年人桡骨远端C型骨折的手术治疗与非手术治疗的疗效差异,评价两种方法的优缺点。方法回顾性分析2009-12—2011-12收治的老年桡骨远端C型骨折68例,按照治疗方法分为A组(手术组)及B组(非手术组),统计分析两组患者的临床资料。结果 A组33例, B组35例,平均随访21.5个月。两组患者的年龄、骨折类型均无差异(P>0.05);术后影像学指标A组优于B组,骨折愈合时间B组优于A组,治疗成本A组大于B组(P<0.05);Cooney评分早期A组优于B组,1年后两组无差异,两组的并发症无差异(P>0.05)。结论老年人桡骨远端C型骨折手术治疗较非手术治疗可获得更好的复位及早期功能,但远期功能恢复无差异。 相似文献
65.
66.
67.
J. Savige L. Amos Frank Ierino H. G. Mack R. C. Andrew Symons P. Hughes 《Ophthalmic genetics》2016,37(4):369-376
Background: Dense deposit disease and atypical hemolytic uremic syndrome are often caused by Complement Factor H (CFH) mutations. This study describes the retinal abnormalities in dense deposit disease and, for the first time, atypical haemolytic uremic syndrome. It also reviews our understanding of drusen pathogenesis and their relevance for glomerular disease. Methods: Six individuals with dense deposit disease and one with atypical haemolytic uremic syndrome were studied from 2 to 40 years after presentation. Five had renal transplants. All four who had genetic testing had CFH mutations. Individuals underwent ophthalmological review and retinal photography, and in some cases, optical coherence tomography, and further tests of retinal function. Results: All subjects with dense deposit disease had impaired night vision and retinal drusen or whitish-yellow deposits. Retinal atrophy, pigmentation, and hemorrhage were common. In late disease, peripheral vision was restricted, central vision was distorted, and there were scotoma from sub-retinal choroidal neovascular membranes and atypical serous retinopathy. Drusen were present but less prominent in the young person with atypical uremic syndrome due to a heterozygous CFH mutation. Conclusions: Drusen are common in forms of C3 glomerulopathy caused by compound heterozygous or heterozygous CFH mutations. They are useful diagnostically but also impair vision. Drusen have an identical composition to glomerular deposits. They are also identical to the drusen of age-related macular degeneration, and may respond to the same treatments. Individuals with a C3 glomerulopathy should be assessed ophthalmologically at diagnosis, and monitored regularly for vision-threatening complications. 相似文献
68.
69.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
70.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献